TRDA VS ETNB Stock Comparison

Performance

TRDA
10/100

TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

ETNB
10/100

ETNB returned -26.21% in the last 12 months. Based on SPY's performance of 11.08%, its performance is below average giving it a score of 10 of 100.

Technicals

TRDA
71/100

TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

ETNB
14/100

ETNB receives a 14 of 100 based on 14 indicators. 1 are bullish, 11 are bearish.

Earnings

TRDA
10/100

TRDA has missed earnings 4 times in the last 20 quarters.

ETNB
10/100

ETNB has missed earnings 6 times in the last 20 quarters.

Profit

TRDA
10/100

Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

ETNB
10/100

Out of the last 20 quarters, ETNB has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

TRDA
51/100

TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

ETNB
43/100

ETNB has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

Sentiment

TRDA

"Sentiment" not found for TRDA

ETNB
66/100

ETNB had a bullish sentiment score of 66.15% across Twitter and StockTwits over the last 12 months. It had an average of 19.12 posts, 4.05 comments, and 7.12 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Entrada Therapeutics, Inc. Common Stock Summary

Nasdaq / TRDA

Healthcare

Biotechnology

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

89bio, Inc. Common Stock Summary

Nasdaq / ETNB

Healthcare

Biotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Power up your portfolio